Abstract
Remdesivir (RDV) is the only antiviral treatment conditionally approved to treat COVID-19 hospitalized patients (1). In Mexico, RDV received an Emergency Use Authorization on March 2021 for hospitalized adults with a confirmed diagnosis of COVID-19 (2). This study assessed to conduct a CEA of the use of RDV in hospitalized patients compared to the standard of care (SoC) in the Mexican context.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have